ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1851

Endotype Discovery in Systemic Lupus Erythematosus Using Multi-Omic Approaches: Toward Precision Insights into Cardiovascular and Renal Damage

Chary López pedrera1, Laurel Woodridge2, Sagrario Corrales3, Juan Rafael Muñoz-Castañeda4, Ana Isabel Torralbo4, Anisur Rahman5, Filipa Farinha2, Rafaela Ortega-Castro6, Pedro Seguí-Azpilcueta7, Ismael Sanchez-Pareja3, Laura muñoz-Barrera3, Christian Merlo-Ruiz8, Desiree Ruiz-Vilchez9, M Carmen Abalos-Aguilera8, Pilar Font10, Nuria Barbarroja11, Marta Alarcon-Riquelme12, Alejandro Escudero Contreras13, MARIA ANGELES AGUIRRE ZAMORANO3, Carlos Pérez Sánchez14, Elizabeth C Jury5 and Tomás Cerdó3, 1Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 2Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, 3Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 4IMIBIC/Hospital Reina Sofía/University of Córdoba, Córdoba, Spain, 5University College London, London, United Kingdom, 6Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 7Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, 8Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 9Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, 10Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 11Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 12Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 13IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 14Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain

Meeting: ACR Convergence 2025

Keywords: Cardiovascular, Lupus nephritis, lupus-like disease, metabolomics, proteomics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1830–1854) Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by marked clinical variability, which complicates both diagnosis and treatment. Among its most severe manifestations are cardiovascular (CV) complications and lupus nephritis (LN), both of which are associated with increased morbidity and mortality. Conventional biomarkers often fall short in capturing the molecular intricacies of these conditions, highlighting the need for integrative multi-omic strategies.

Methods: In this study, proteomic and metabolomic analyses were combined to uncover molecular signatures linked to CV risk and LN. Serum samples from 199 SLE patients were examined using proximity extension assays for proteomic profiling and nuclear magnetic resonance (NMR) spectroscopy for metabolomic analysis. In vitro assays were performed by treating HUVECs and HK2 cells with serum from SLE patients to assess endothelial and renal proteomic responses. Ex vivo experiments involved culturing rat kidney slices with the same sera to evaluate inflammatory signalling through p65 immunofluorescence.

Results: Unsupervised clustering based on proteomic data identified two patient subgroups: one with high disease severity (HDS) and another with low disease severity (LDS). The HDS group showed increased levels of inflammatory proteins (e.g., IL6, CD40, CXCL9) and metabolites (e.g., creatinine, citrate), which were associated with CV risk and renal involvement. Using machine learning, patients were accurately classified into HDS and LDS groups (AUC = 0.77), with biomarkers such as citrate and LDL subclasses playing a key role.These results were validated in an independent patient cohort, confirming the robustness of the identified molecular patterns. In vitro assays revealed that serum from HDS patients induced endothelial dysfunction in HUVECs and triggered inflammatory responses in HK2 kidney cells, including the upregulation of proteins involved in tissue damage and immune activation. Furthermore, ex vivo experiments using rat kidney slices demonstrated NF-κB pathway activation in tissues exposed to HDS serum.

Conclusion: Overall, this study provides compelling evidence that CVS risk and LN in SLE are associated with distinct proteomic-metabolomic signatures that reflect underlying disease mechanisms. The integration of omics data with functional assays offers valuable insights into the molecular drivers of organ-specific damage in SLE. These findings might pave the way for biomarker-driven diagnostic tools and personalized therapeutic strategies based on patient stratification, aiming to mitigate disease-related complications.Supported by ISCIII (PI24/00959, CD21/00187 and RICOR-24/0007/0019), co-financed by European Union, and MINECO (RYC2021-033828-I/PID2022-141500OA-I00).


Disclosures: C. López pedrera: None; L. Woodridge: None; S. Corrales: None; J. Muñoz-Castañeda: None; A. Torralbo: None; A. Rahman: None; F. Farinha: None; R. Ortega-Castro: None; P. Seguí-Azpilcueta: None; I. Sanchez-Pareja: None; L. muñoz-Barrera: None; C. Merlo-Ruiz: None; D. Ruiz-Vilchez: None; M. Abalos-Aguilera: None; P. Font: None; N. Barbarroja: None; M. Alarcon-Riquelme: None; A. Escudero Contreras: None; M. AGUIRRE ZAMORANO: None; C. Pérez Sánchez: None; E. C Jury: None; T. Cerdó: None.

To cite this abstract in AMA style:

López pedrera C, Woodridge L, Corrales S, Muñoz-Castañeda J, Torralbo A, Rahman A, Farinha F, Ortega-Castro R, Seguí-Azpilcueta P, Sanchez-Pareja I, muñoz-Barrera L, Merlo-Ruiz C, Ruiz-Vilchez D, Abalos-Aguilera M, Font P, Barbarroja N, Alarcon-Riquelme M, Escudero Contreras A, AGUIRRE ZAMORANO M, Pérez Sánchez C, C Jury E, Cerdó T. Endotype Discovery in Systemic Lupus Erythematosus Using Multi-Omic Approaches: Toward Precision Insights into Cardiovascular and Renal Damage [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/endotype-discovery-in-systemic-lupus-erythematosus-using-multi-omic-approaches-toward-precision-insights-into-cardiovascular-and-renal-damage/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/endotype-discovery-in-systemic-lupus-erythematosus-using-multi-omic-approaches-toward-precision-insights-into-cardiovascular-and-renal-damage/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology